Approved Study Database

Ref. No. Scientific Title Principal investigator
2008.068 A Phase 1 / 2 Study of CMC-544 Administered in Combination with Rituximab in Subjects with Follicular or Diffuse Large B-Cell Non-Hodgkin’s Lymphoma Prof. WONG Raymond Siu Ming
2009.488 A study of the pharmacokinetics of Nilotinib (Tasigna) in Chinese patients with imatinib-resistant and/or Dr. WONG Raymond Siu Ming
2012.419 An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease Dr. WONG Raymond Siu Ming
2009.489 A multi-center, randomized, double-blind, placebo-controlled clinical trial of deferasirox in patients with myelodysplastic syndromes (low/int-1 risk) and tranfusional iron overload (TELESTO) Dr. WONG Raymond Siu Ming
2012.257 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma Dr. WONG Raymond Siu Ming
2014.111 A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. Dr. WONG Raymond Siu Ming
2013.430 AN OPEN-LABEL BOSUTINIB TREATMENT EXTENSION STUDY FOR SUBJECTS WITH CHRONIC MYELOID LEUKEMIA (CML) WHO HAVE PREVIOUSLY PARTICIPATED IN BOSUTINIB STUDIES B1871006 OR B1871008 Dr. WONG Raymond Siu Ming
2009.308 A Phase 2 Study of Inotuzumab Ozogamicin (CMC-544) in Subjects With Indolent Non-Hodgkin’s Lymphoma (NHL) That is Refractory to or has Relapsed After Rituximab and Chemotherapy or Radioimmunotherapy Dr. WONG Raymond Siu Ming
2010.176 B-LONG: An Open-Label, Multicenter Evaluation of the Safety, Pharmacokinetics, and Efficacy of Recombinant, Long-acting Coagulation Factor IX Fc fusion (rFIXFc) in the Prevention and Treatment of Bleeding in Previously Treated Subjects With Severe Hemophilia B Dr. Wong Raymond Siu Ming
Raymond Siu Ming WONG
2011.538 An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A Dr. WONG Raymond Siu Ming
2007.017 LENS Dr. WONG Raymond Siu Ming
2009.573 An Open-label, Phase 1 Study of R-CVP or R-GDP in Combination With Inotuzumab Ozogamicin in Subjects With CD22-Positive Non-Hodgkin’s Lymphoma Dr. Wong Raymond Siu Ming
2010.030 A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma Dr. WONG Raymond Siu Ming
2007.186 A Phase 3, Randomized, Double-Blind, Parallel-Group, Multi-Center Study of the Safety and Efficacy of Apixaban for Prophylaxis of Venous Thromboembolism in Acutely I11 Medical Subjects During and Following Hospitalization Dr. WONG Raymond Siu Ming
2011.479 An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B Dr. WONG Raymond Siu Ming
2014.112 Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag. Dr. WONG Raymond Siu Ming
2009.494 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman Disease Dr. WONG Raymond Siu Ming
2011.395 A Three-part Study of Eltrombopag in Thrombocytopenic Subjects with Myelodysplastic Syndromes or Acute Myeloid Leukemia (Part 1: open-label, Part 2: randomized, double-blind, Part 3: extension). Dr. WONG Raymond Siu Ming
2013.269 A RANDOMIZED, OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE PATIENT PREFERENCE WITH SUBCUTANEOUS ADMINISTRATION OF RITUXIMAB VERSUS INTRAVENOUS RITUXIMAB IN PREVIOUSLY UNTREATED PATIENTS WITH CD20+ DIFFUSE LARGE B-CELL LYMPHOMA OR CD20+ FOLLICULAR NON-HODGKIN’S LYMPHOMA GRADES 1, 2 OR 3A Dr. WONG Raymond Siu Ming
2012.305 A Randomized, Open Label Study of Ofatumumab and Bendamustine Combination Therapy Compared with Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin’s Lymphoma Unresponsive to Rituximab or a Rituximab-Containing Regimen During or Within Six Months of Treatment. Dr. WONG Raymond Siu Ming
2011.278 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy Dr. WONG Raymond Siu Ming
2012.292 A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma Dr. WONG Raymond Siu Ming
2009.309 An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed / Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation Dr. WONG Raymond Siu Ming
2018.471 An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of PEGCETACOPLAN in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) Dr. WONG Raymond Siu Ming
王紹明
2019.229 Real-world Evidence of the Use of Carfilzomib Among Patients With Relapsed/Refractory Multiple Myeloma in Asia Pacific Dr. WONG Raymond Siu Ming
王紹明
2020.156 A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Dr. WONG Raymond Siu Ming
王紹明
2019.481 AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA Dr. WONG Raymond Siu Ming
2019.512 A retrospective analysis of risk factors and outcomes of cancer-associated venous thromboembolism in Chinese patients Dr. WONG Raymond Siu Ming
2019.286 A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Dr. WONG Raymond Siu Ming
王紹明
2014.006 Myeloproliferative neoplasms Epidemiological Registry in Growing and Emerging markets - The MERGE Study Dr. WONG Raymond Siu Ming
2016.534 A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Dr. WONG Raymond Siu Ming
王紹明
2015.147 A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2 Dr. WONG Raymond Siu Ming
王紹明
2015.087 Open-label, uncontrolled Phase II trial of intravenous PI3K inhibitor BAY 80-6946 in patients with relapsed, indolent or aggressive Non-Hodgkin’s lymphomas (Part B) Dr. WONG Raymond Siu Ming
2016.688 Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) Including Those with the 17p Deletion or TP53 Mutation OR Those Who Have Received Prior Treatment with a B-Cell Receptor Inhibitor Dr. WONG Raymond Siu Ming
王紹明醫生
2014.635 Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world Dr. WONG Raymond Siu Ming
2015.670 Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A Dr. WONG Raymond Siu Ming
王紹明醫生
2015.579 A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults with Thrombotic Microangiopathies Dr. WONG Raymond Siu Ming
王紹明
2015.580 A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation Dr. WONG Raymond Siu Ming
王紹明
2015.506 A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) – CHRONOS-3 Dr. WONG Raymond Siu Ming
王紹明
2016.400 A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma. Dr. WONG Raymond Siu Ming
王紹明醫生
2014.269 A randomized, double-blind, placebo-controlled, phase III, multi-centre study of eltrombopag or placebo in combination with azacitidine in subjects with IPSS intermediate-1, intermediate 2 and high-risk myelodysplastic syndrome (MDS) Dr. WONG Raymond Siu Ming
2016.631 A Phase IV multicenter, observational study in Chronic Immune Thrombocytopenia patients on eltrombopag treatment in emerging markets (CITE Study) Dr. WONG Raymond Siu Ming
王紹明
2016.399 A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old with Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM-First) Dr. WONG Raymond Siu Ming
王紹明
2015.010 The hepato-protective effects of umbilical cord-derived stem cell on acetaminophen induced liver injury. Dr. WONG Raymond Siu Ming
2017.267 A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL) - CHRONOS-4 Dr. WONG Raymond Siu Ming
王紹明
2013.608 An open-label, single-arm, Phase Ib/II study of AEB071 (a protein kinase C inhibitor) and everolimus (mTOR inhibitor) in patients with CD79-mutant or ABC subtype diffuse large B-cell lymphoma Dr. WONG Raymond Siu Ming
2016.178 A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma Dr. WONG Raymond Siu Ming
王紹明醫生
2017.002 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma Dr. WONG Raymond Siu Ming
王紹明醫生
2017.452 A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH). – PADDOCK – Dr. WONG Raymond Siu Ming
王紹明
2016.463 A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network Dr. WONG Raymond Siu Ming
王紹明

Page 257 of 289.